S&P 500   3,783.28
DOW   30,273.87
QQQ   281.98
5 Tips I Wish I Knew Before Starting My Business
Bonner’s “4th and Final Prediction”—First 3 came true, will this too? (Ad)
Live Updates: Russia-Ukraine War
Too Soon: 3 Reasons to Wait on DocuSign Stock
Bonner’s “4th and Final Prediction”—First 3 came true, will this too? (Ad)
WTO predicts trade growth to slow next year amid crises
OPEC+ makes big oil cut to boost prices; pump costs may rise
Bonner’s “4th and Final Prediction”—First 3 came true, will this too? (Ad)
Stocks slump as Wall Street’s big rally fades, yields rise
Rite-Aid Sings a Familiar Tune That Investors Don’t Want to Hear
S&P 500   3,783.28
DOW   30,273.87
QQQ   281.98
5 Tips I Wish I Knew Before Starting My Business
Bonner’s “4th and Final Prediction”—First 3 came true, will this too? (Ad)
Live Updates: Russia-Ukraine War
Too Soon: 3 Reasons to Wait on DocuSign Stock
Bonner’s “4th and Final Prediction”—First 3 came true, will this too? (Ad)
WTO predicts trade growth to slow next year amid crises
OPEC+ makes big oil cut to boost prices; pump costs may rise
Bonner’s “4th and Final Prediction”—First 3 came true, will this too? (Ad)
Stocks slump as Wall Street’s big rally fades, yields rise
Rite-Aid Sings a Familiar Tune That Investors Don’t Want to Hear
S&P 500   3,783.28
DOW   30,273.87
QQQ   281.98
5 Tips I Wish I Knew Before Starting My Business
Bonner’s “4th and Final Prediction”—First 3 came true, will this too? (Ad)
Live Updates: Russia-Ukraine War
Too Soon: 3 Reasons to Wait on DocuSign Stock
Bonner’s “4th and Final Prediction”—First 3 came true, will this too? (Ad)
WTO predicts trade growth to slow next year amid crises
OPEC+ makes big oil cut to boost prices; pump costs may rise
Bonner’s “4th and Final Prediction”—First 3 came true, will this too? (Ad)
Stocks slump as Wall Street’s big rally fades, yields rise
Rite-Aid Sings a Familiar Tune That Investors Don’t Want to Hear
S&P 500   3,783.28
DOW   30,273.87
QQQ   281.98
5 Tips I Wish I Knew Before Starting My Business
Bonner’s “4th and Final Prediction”—First 3 came true, will this too? (Ad)
Live Updates: Russia-Ukraine War
Too Soon: 3 Reasons to Wait on DocuSign Stock
Bonner’s “4th and Final Prediction”—First 3 came true, will this too? (Ad)
WTO predicts trade growth to slow next year amid crises
OPEC+ makes big oil cut to boost prices; pump costs may rise
Bonner’s “4th and Final Prediction”—First 3 came true, will this too? (Ad)
Stocks slump as Wall Street’s big rally fades, yields rise
Rite-Aid Sings a Familiar Tune That Investors Don’t Want to Hear
NASDAQ:RGEN

Repligen - RGEN Stock Forecast, Price & News

$220.56
+7.01 (+3.28%)
(As of 10/5/2022 12:00 AM ET)
Add
Compare
Today's Range
$210.73
$221.95
50-Day Range
$179.33
$256.21
52-Week Range
$137.21
$306.98
Volume
620,582 shs
Average Volume
489,445 shs
Market Capitalization
$12.24 billion
P/E Ratio
79.62
Dividend Yield
N/A
Price Target
$276.00

Repligen MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
25.1% Upside
$276.00 Price Target
Short Interest
Bearish
5.12% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.58
Upright™ Environmental Score
News Sentiment
0.64mentions of Repligen in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$15.73 M Sold Last Quarter
Proj. Earnings Growth
11.01%
From $3.18 to $3.53 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.57 out of 5 stars

Medical Sector

176th out of 1,072 stocks

Biological Products, Except Diagnostic Industry

27th out of 169 stocks

RGEN stock logo

About Repligen (NASDAQ:RGEN) Stock

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and SpectraFlo dynamic dialysis systems; and ProConnex single-use hollow fiber. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. Repligen Corporation was incorporated in 1981 and is headquartered in Waltham, Massachusetts.

Receive RGEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Repligen and its competitors with MarketBeat's FREE daily newsletter.

RGEN Stock News Headlines

MarketBeat: Week in Review 9/12 – 9/16 (RGEN)
In volatile markets, rely on MarketBeat to keep you focused on your investment objectives. Here are some of our most popular articles from this week
Why Medical Products Maker Repligen May Be A Potential Buy
Medical products maker Repligen has a long history of trouncing sales and earnings views, and it just boosted its full-year sales guidance. Is the stock a buy?
Repligen To Host Investor Day 2022 - GlobeNewswire
Repligen To Host Investor Day 2022
See More Headlines
Receive RGEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Repligen and its competitors with MarketBeat's FREE daily newsletter.

RGEN Company Calendar

Last Earnings
8/02/2022
Today
10/05/2022
Next Earnings (Estimated)
10/27/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:RGEN
CUSIP
75991610
Employees
1,852
Year Founded
1981

Price Target and Rating

Average Stock Price Forecast
$276.00
High Stock Price Forecast
$330.00
Low Stock Price Forecast
$213.00
Forecasted Upside/Downside
+25.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

Net Income
$128.29 million
Pretax Margin
25.01%

Debt

Sales & Book Value

Annual Sales
$670.53 million
Cash Flow
$4.21 per share
Book Value
$31.65 per share

Miscellaneous

Free Float
54,881,000
Market Cap
$12.24 billion
Optionable
Optionable
Beta
1.11

Social Links


Key Executives

  • Mr. Anthony J. HuntMr. Anthony J. Hunt (Age 58)
    Pres, CEO & Director
    Comp: $2.1M
  • Mr. Jon K. SnodgresMr. Jon K. Snodgres (Age 56)
    Chief Financial Officer
    Comp: $860.08k
  • Mr. James R. BylundMr. James R. Bylund (Age 58)
    Chief Operating Officer
    Comp: $725.55k
  • Ms. Christine GebskiMs. Christine Gebski (Age 53)
    Sr. VP of Filtration & Chromatography
    Comp: $685.06k
  • Mr. Ralf KuriyelMr. Ralf Kuriyel (Age 63)
    Sr. VP of R&D
    Comp: $708.15k
  • Ms. Sondra S. Newman
    Global Head of Investor Relations
  • Ms. Kimberly Cornwell
    Global Head of Legal & Gen. Counsel
  • Mr. Stephen Tingley
    VP & Head of Global Sales
  • Ms. Rachel Goodrich
    VP of Marketing
  • Mr. James Slaughter
    Chief HR Officer













RGEN Stock - Frequently Asked Questions

Should I buy or sell Repligen stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Repligen in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" RGEN shares.
View RGEN analyst ratings
or view top-rated stocks.

What is Repligen's stock price forecast for 2022?

6 brokers have issued 1-year price objectives for Repligen's stock. Their RGEN share price forecasts range from $213.00 to $330.00. On average, they expect the company's share price to reach $276.00 in the next twelve months. This suggests a possible upside of 25.1% from the stock's current price.
View analysts price targets for RGEN
or view top-rated stocks among Wall Street analysts.

How have RGEN shares performed in 2022?

Repligen's stock was trading at $264.84 at the beginning of 2022. Since then, RGEN shares have decreased by 16.7% and is now trading at $220.56.
View the best growth stocks for 2022 here
.

When is Repligen's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, October 27th 2022.
View our RGEN earnings forecast
.

How were Repligen's earnings last quarter?

Repligen Co. (NASDAQ:RGEN) announced its quarterly earnings data on Tuesday, August, 2nd. The biotechnology company reported $0.91 earnings per share for the quarter, topping analysts' consensus estimates of $0.72 by $0.19. The biotechnology company earned $207.63 million during the quarter, compared to analysts' expectations of $189.06 million. Repligen had a net margin of 20.47% and a trailing twelve-month return on equity of 11.18%. The business's quarterly revenue was up 27.4% on a year-over-year basis. During the same period in the previous year, the firm posted $0.79 EPS.

What guidance has Repligen issued on next quarter's earnings?

Repligen issued an update on its FY 2022 earnings guidance on Tuesday, August, 9th. The company provided EPS guidance of $3.13-$3.20 for the period, compared to the consensus earnings per share estimate of $3.09. The company issued revenue guidance of $790.00 million-$810.00 million, compared to the consensus revenue estimate of $788.55 million.

What is Tony J. Hunt's approval rating as Repligen's CEO?

13 employees have rated Repligen Chief Executive Officer Tony J. Hunt on Glassdoor.com. Tony J. Hunt has an approval rating of 52% among the company's employees. This puts Tony J. Hunt in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Repligen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Repligen investors own include NVIDIA (NVDA), Alibaba Group (BABA), Salesforce (CRM), Block (SQ), Advanced Micro Devices (AMD), DocuSign (DOCU), Walt Disney (DIS), Netflix (NFLX), Tesla (TSLA) and ServiceNow (NOW).

What is Repligen's stock symbol?

Repligen trades on the NASDAQ under the ticker symbol "RGEN."

How do I buy shares of Repligen?

Shares of RGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Repligen's stock price today?

One share of RGEN stock can currently be purchased for approximately $220.56.

How much money does Repligen make?

Repligen (NASDAQ:RGEN) has a market capitalization of $12.24 billion and generates $670.53 million in revenue each year. The biotechnology company earns $128.29 million in net income (profit) each year or $2.77 on an earnings per share basis.

How many employees does Repligen have?

The company employs 1,852 workers across the globe.

Does Repligen have any subsidiaries?
The following companies are subsidiares of Repligen: ARTeSYN Biosolutions Holdings Ireland Limite, C Technologies Inc., Engineered Molding Technology LLC, Non-Metallic Solutions Inc, Repligen (Shanghai) Biotechnology Co. Ltd., Repligen Europe B.V., Repligen GmbH, Repligen India Private Limited, Repligen Japan LLC, Repligen Korea Co. Ltd., Repligen Singapore Pte. Ltd., Repligen Sweden AB, and Spectrum Lifesciences LLC.
Read More
How can I contact Repligen?

Repligen's mailing address is 41 SEYON STREET BUILDING 1 SUITE 100, WALTHAM MA, 02453. The official website for the company is www.repligen.com. The biotechnology company can be reached via phone at (781) 250-0111, via email at investors@repligen.com, or via fax at 781-250-0115.

This page (NASDAQ:RGEN) was last updated on 10/6/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access members have access to premium reports, best-in-class portfolio monitoring tools, and our latest stock picks.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies, and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.